$AUPH:NASDAQ · Aurinia Pharmaceuticals Inc.
Conviction from: NASDAQ
Aurinia Pharmaceuticals Inc., a biopharmaceutical company, engages in delivering therapies to people living with autoimmune diseases with high unmet medical needs in the United States and Japan.
More about this company
Aurinia Pharmaceuticals Inc., a biopharmaceutical company, engages in delivering therapies to people living with autoimmune diseases with high unmet medical needs in the United States and Japan. The company offers LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis. It also develops aritinercept, a dual inhibitor of B cell-activating factor and proliferation-inducing ligand for the potential treatment of autoimmune diseases. The company was founded in 1993 and is headquartered in Edmonton, Canada.
Not currently held by tracked 13F filers — this page aggregates activist, insider, politician and research activity.
Beyond 13F — activists, insiders, politicians & research
| Filed | Form | Activist | % of class | Conviction | |
|---|
| 2026-03-25 | SCHEDULE 13D/A | TANG CAPITAL MANAGEMENT LLC | 9.2% | Med | filing |
| 2026-03-03 | SCHEDULE 13D/A | TANG CAPITAL MANAGEMENT LLC | 9.2% | Med | filing |
| Filed | Insider | Role | Shares | Value | |
|---|
| 2026-03-03 | TANG KEVIN | director | 900,000 | $12,688,806 | Form 4 |